{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The DMC procedures and safety data to be reviewed by the DMC are described in the DMC', 'charter. In the above capacities, the DMC is advisory to the Sponsor. The Sponsor is responsible', 'for promptly reviewing and for taking into account in a timely manner the recommendations of', 'the DMC in terms of trial continuation with or without alterations or of potential trial termination.', 'Property of the Sanofi Group - strictly confidential', 'Page 43', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '7', 'SELECTION OF PATIENTS', '7.1', 'INCLUSION CRITERIA', 'I 01. Children 6 to <12 years of age, with a physician diagnosis of persistent asthma for', '>12 months prior to screening based on clinical history and examination, pulmonary', 'function parameters according to Global initiative for asthma (GINA) 2015 Guidelines and', 'the following criteria:', '-', 'Existing background therapy of medium-dose ICS with second a controller medication', '(ie, LABA, LTRA), Long acting muscarinic antagonist (LAMA), or methylxanthines)', 'or high-dose ICS alone or high-dose ICS with second controller, for at least 3 months', 'with a stable dose > 1 month prior to Screening Visit 1 (dose levels as per', 'Appendix A).', '-', 'Pre-bronchodilator FEV1 95% of predicted normal or pre bronchodilator', 'FEV1/forced vital capacity (FVC) ratio <0.85 at Screening and Baseline Visits.', '-', 'Reversibility of at least 10% in FEV1 after the administration of 200 to 400 mcg', '(2 to 4 puffs with metered-dose inhaler [MDI]) of albuterol/salbutamol or 45 to 90 mcg', '(2 to 4 puffs with MDI) of levalbuterol/levosalbutamol reliever medication before', 'randomization (up to 3 opportunities during the same visit are allowed with a', 'maximum of 12 puffs of reliever medication if tolerated by the patient).', 'Note: A maximum of 3 visits to meet the qualifying criterion of reversibility may be', \"made during the screening period and prior to the patient's randomization.\", 'For patients that will have an additional and last attempt of reversibility testing (for', \"eligibility) at the Baseline Visit 2 before patient's randomization into the interactive\", 'response technology (IRT), the post-bronchodilator FEV1 will come from the result of', 'this reversibility test.', 'Note: Documented reversibility or positive airway hyper-responsiveness to', 'methacholine within 12 months prior to Screening V1 is considered acceptable.', '-', 'Must have experienced, within 1 year prior to Screening Visit 1, defined as any of the', 'following events:', 'a) Treatment with a systemic corticosteroid (SCS, oral or parenteral) prescribed by a', 'healthcare professional for worsening asthma at least once or,', 'b) Hospitalization or emergency medical care visit for worsening asthma.', '-', 'Evidence of uncontrolled asthma, with at least one of the following criteria during the', '4 (+1)-week Screening Period:', 'c) Asthma Control Questionnaire-Interviewer Administered (ACQ-IA) ACQ-5 score', '>1.5 on at least one day of the Screening Period including V2.', 'd) Use of reliever medication (ie, albuterol/salbutamol or', 'levalbuterol/levosalbutamol), other than as a preventive for exercise induced', 'Property of the Sanofi Group - strictly confidential', 'Page 44', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'bronchospasm, on 3 or more days/per week on at least one week during the', 'Screening Period.', 'e) Sleep awakening due to asthma that required the use of reliever medication at least', 'once during the Screening Period.', 'f)', 'Asthma symptoms 3 or more days/week on at least one week during the Screening', 'Period.', 'I 02. Willing and able to comply with clinic visits and study-related procedures.', 'I 03. With parent(s)/caregiver(s)/legal guardian(s) able to understand the study requirements.', 'I 04. Patients >6 years of age (or above an age determined by the Institutional Review Board', '[IRB]/Independent Ethics Committee [IEC] and in accordance with the local regulations', 'and requirements) must provide written informed assent, and their', 'parent(s)/caregiver(s)/legal guardian(s) must provide written informed consent.', 'I 05.', 'atients/parent(s)/caregiver(s)/legal guardian(s), as appropriate, must be able to understand', 'and complete study-related questionnaires.', '7.2', 'EXCLUSION CRITERIA', 'Patients who have met all the above inclusion criteria listed in Section 7.1 will be screened for the', 'following exclusion criteria which are sorted and numbered in the following subsections:', '7.2.1 Exclusion Criteria Related to Study Methodology', 'E 01. Patients <6 or >12 years of age', 'E 02. Patients <16 kg bw', 'E 03. Any other chronic lung disease (cystic fibrosis, bronchopulmonary dysplasia, etc) which', 'may impair lung function.', 'E 04. A subject with any history of life-threatening asthma (eg, requiring intubation).', 'E 05. Co-morbid disease that might interfere with the evaluation of investigational medicinal', 'product (IMP)', 'E 06. History of malignancy of any kind.', 'E 07. Inability to follow the procedures of the study (eg, due to language problems or', 'psychological disorders).', 'E', '08. Anti-immunoglobulir E (IgE) therapy (omalizumab) within 130 days prior to Visit 1 or', 'any other biologic therapy/immunosuppressant to treat inflammatory disease or', 'autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, systemic lupus', 'Property of the Sanofi Group - strictly confidential', 'Page 45', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}